

Lucky Group (H.K) Limited

June.03,2021

Federal Communications Commission
445 12th Street SW
Washington, DC 20554

Subject: Limited Agency Agreement
Lucky Group (H.K) Limited
FCC ID: 2ACO3-18818

To Whom It May Concern:

We, *Lucky Group (H.K) Limited*, hereby authorized Intertek Testing Services to act as our Agent for the purpose of preparing application for FCC ID number 2ACO3-18818 under all applicable parts of the FCC rules and regulations.


The effective date of this limited agency agreement is *June.03,2021*. The Limited Agency Agreement expires on *June.03,2022*, unless sooner terminated or extended by written notice to Intertek Testing Services and the Federal Communications Commission.

This is to advise that we are in full compliance with the Anti-Drug Abuse Act. The applicant is not subject to a denial of federal benefits pursuant to Section 5301 of the Anti-Drug Act of 1988, 21 U.S.C. 862, and no party to the application is subject to a denial of federal benefits pursuant to that section.

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,

Signature:



[Type Name]: **Jacob Yeh**

[Type Title]: **President**

- Tune-up Procedure
- Parts List
- Test Setup Photos
- External Photos
- Internal Photos
- Users Manual

Rationale for request for confidentiality:

We have invested considerable time and materials in research and development to produce the referenced product.


Permanent confidentiality: Disclosure of the permanently confidential portions of this application to competitors would not only give them significant competitive advantages in developing similar products, but would also disclose successful implementation of unpublished, leading edge technology developed by us.

Short-term confidentiality: Disclosure of the short-term confidential portions of this application during the period of importation and/or distribution would reveal key aspects of proprietary technology to competitors and diminish the value of our investment in research and development.

If you have questions or need further information, please contact the undersigned.

Sincerely,

Signature:



[Title]: **President**

[Date]: **June.03, 2021**